Get access

Palifermin-induced acral erythrodysaesthesia variant in the treatment of acute myeloid leukaemia


  • Olivia Milne, MB BS. Briony Cutts, MB BS. Catriona McLean, FRCPA. Douglas Gin, FRACD.

Dr Olivia Milne, Department of Dermatology, The Alfred Hospital, PO Box 315, Prahran, Victoria, 3181. Email:


The recombinant human keratinocyte growth factor, palifermin, offers a potential means of reducing or preventing mucositis in patient undergoing intensive cancer treatments. This case report details the development of acral erythrodysaesthesia in one patient who underwent palifermin treatment prior to high-intensity re-induction chemotherapy for acute myeloid leukaemia.